The investment portfolio of Octopus AIM VCT 2 plc (the "Company") as at 14 June 2017 is as follows (the valuations being the unaudited valuations, at bid price, as at 31 May 2017):
Investee Company | Sector | Book cost (£000) | Movement in valuation (£000) | Fair Value (£000) |
Breedon Group plc | Construction & Building | 573 | 3,627 | 4,200 |
Quixant plc | Technology Hardware | 465 | 3,501 | 3,966 |
Animalcare Group plc | Pharmaceuticals & Biotech | 824 | 2,606 | 3,430 |
GB Group plc | Support Services | 477 | 2,631 | 3,108 |
IDOX plc | Software | 356 | 2,379 | 2,735 |
Gear4music Holdings plc | Media | 372 | 1,780 | 2,152 |
Craneware plc | Software | 479 | 1,537 | 2,016 |
Learning Technologies Group plc | Support Services | 880 | 1,008 | 1,888 |
Brooks Macdonald Group plc | Finance | 610 | 1,213 | 1,823 |
Staffline Recruitment Group plc | Support Services | 225 | 1,540 | 1,765 |
RWS Holdings plc | Support Services | 249 | 1,393 | 1,642 |
Netcall plc | Telecommunication Services | 356 | 1,081 | 1,437 |
Adept Telecom plc | Telecommunication Services | 502 | 716 | 1,218 |
Ergomed plc | Pharmaceuticals & Biotech | 960 | 228 | 1,188 |
DP Poland plc | Leisure & Hotels | 364 | 764 | 1,128 |
Gooch & Housego plc | Electronic & Electrical | 326 | 784 | 1,110 |
Yu Group plc | Utilities | 470 | 572 | 1,042 |
Restore plc | Support Services | 311 | 703 | 1,014 |
Clinigen Group plc | Pharmaceuticals & Biotech | 625 | 295 | 920 |
EKF Diagnostics Holdings plc | Health | 864 | 43 | 907 |
Advanced Medical Solutions Group plc | Pharmaceuticals & Biotech | 505 | 384 | 889 |
Next Fifteen Communications Group plc | Media | 458 | 417 | 875 |
Vertu Motors plc | General Retailers | 777 | 71 | 848 |
Plastics Capital plc | Engineering & Machinery | 485 | 346 | 831 |
Escher Group Holdings plc | Software | 753 | 65 | 818 |
CityFibre plc | Telecommunication Services | 739 | 40 | 779 |
Brady plc | Software | 647 | 127 | 774 |
Omega Diagnostics Group plc | Health | 318 | 440 | 758 |
TLA Worldwide plc | Media | 538 | 188 | 726 |
Ideagen plc | Software | 280 | 433 | 713 |
Escape Hunt plc | Leisure & Hotels | 659 | 0 | 659 |
Tasty plc | Leisure & Hotels | 336 | 311 | 647 |
Futura Medical plc | Pharmaceuticals & Biotech | 645 | (23) | 622 |
Cello Group plc | Media | 205 | 391 | 596 |
Judges Scientific plc | Electronic & Electrical | 209 | 381 | 590 |
Abcam plc | Pharmaceuticals & Biotech | 358 | 229 | 587 |
Cambridge Cognition Holdings plc | Health | 400 | 171 | 571 |
Nasstar plc | Software | 320 | 224 | 544 |
Velocity Composites plc | Industrial | 533 | 0 | 533 |
Faron Pharmaceuticals Oy | Pharmaceuticals & Biotech | 230 | 269 | 499 |
LoopUp Group plc | Software | 320 | 170 | 490 |
Gamma Communications plc | Telecommunication Services | 326 | 161 | 487 |
Vectura Group plc | Pharmaceuticals & Biotech | 332 | 138 | 470 |
Haydale Graphene Industries plc | Chemicals | 399 | 50 | 449 |
SQS Software Quality Systems AG | Software | 207 | 201 | 408 |
Mattioli Woods plc | Finance | 101 | 289 | 390 |
Scientific Digital Imaging plc | Electronic & Electrical | 119 | 245 | 364 |
Sinclair IS Pharma plc | Pharmaceuticals & Biotech | 274 | 74 | 348 |
Maxcyte Inc | Pharmaceuticals & Biotech | 340 | (19) | 321 |
Iomart Group plc | Software | 178 | 123 | 301 |
Access Intelligence plc | Software | 446 | (72) | 374 |
Osirium Technologies plc | Electronic & Electrical | 500 | (208) | 292 |
UP Global Sourcing Holdings plc | Household Goods & Textiles | 182 | 105 | 287 |
WANdisco plc | Software | 96 | 152 | 248 |
FreeAgent Holdings plc | Media | 185 | 46 | 231 |
TP Group plc | Engineering & Machinery | 452 | (222) | 230 |
Hasgrove plc* | Media | 153 | 59 | 212 |
MyCelx Technologies Corporation | Oil Equipment | 980 | (679) | 301 |
Microsaic Systems plc | Engineering & Machinery | 722 | (534) | 188 |
Sphere Medical Holding plc | Health | 400 | (219) | 181 |
Enteq Upstream plc | Oil Services | 687 | (516) | 171 |
Midatech Pharma plc | Pharmaceuticals & Biotech | 400 | (243) | 157 |
Nektan Limited | Software | 893 | (420) | 473 |
Oxford Pharmascience Group plc | Pharmaceuticals & Biotech | 900 | (765) | 135 |
Tyratech Inc | Chemicals | 400 | (280) | 120 |
Medica Group plc | Health | 63 | 41 | 104 |
Mears Group plc | Support Services | 51 | 44 | 95 |
ReNeuron Group plc | Pharmaceuticals & Biotech | 216 | (134) | 82 |
Genedrive Plc | Pharmaceuticals & Biotech | 140 | (70) | 70 |
Rated People Ltd* | Software | 236 | (178) | 58 |
Fusionex International plc | Software | 188 | (132) | 56 |
Proxama plc | Software | 509 | (470) | 39 |
1Spatial plc | Software | 200 | (178) | 22 |
Work Group plc | Support Services | 379 | (365) | 14 |
Bond International Software plc | Software | 4 | 0 | 4 |
Current Liquidity Investments
Investee Company | Sector | Book cost (£000) | Movement in valuation (£000) | Fair Value (£000) |
Money Market Funds | n/a | 4,420 | 6 | 4,426 |
Octopus Portfolio Manager - Conservative Capital Growth | n/a | 3,600 | 267 | 3,867 |
Octopus Portfolio Manager - Defensive Capital Growth | n/a | 3,600 | 187 | 3,787 |
Octopus UK Micro Cap Growth Fund | n/a | 1,100 | 296 | 1,396 |
Since 31 May 2017 there has been one follow on investment with a cost of £313,000.
Since 31 May 2017 there has been one disposal, the proceeds of which totalled £104,000 (cost £81,000).
Unless otherwise stated, all the investments set out above : |
1. are quoted on AIM or on the London Stock Exchange Full List: |
2. represent equity investments except in the case of Nektan and Access Intelligence which include investment via loan stock: and |
3. are in portfolio companies incorporated in the UK with the exception of: |
Escher - Ireland |
Mycelx - USA |
SQS - Germany |
Nektan - Gibraltar |
Faron Pharmaceuticals Oy - Finland |
MayCyte Inc - USA |
*Denotes private company |
As at 31 May 2017, Octopus AIM 2's portfolio of investments including current liquidity investments comprised, by value, £74.3m and the net assets of the Company were £75.6m. Octopus AIM 2's investment portfolio is in a variety of sectors and comprises 70 UK AIM-quoted companies, 2 non-AIM companies, 4 fully listed companies on the premium segment of the Official List, none listed on NASDAQ and none traded on the NEX Exchange.
For further information, please contact:
Nicola Board
Octopus Investments Limited
Tel: 0800 316 2295